Background: Etomidate is frequently selected over propofol for induction of anaesthesia because of a putatively favourable haemodynamic profile, but data confirming this perception are limited. Methods: Patients undergoing cardiac surgery were randomised to induction of anaesthesia with propofol or etomidate. Phase I (n¼75) was conducted as open-label, whereas Phase II (n¼75) was double blind. Mean arterial blood pressure (MAP) and boluses of vasopressor administered after induction were recorded. The primary endpoint was the area under the curve below baseline MAP (MAP-time integral) during the 10 min after induction. Secondary endpoints were the use of vasopressors over the same period, and the effect of blinding on the aforementioned endpoints. Groups were compared using regression models with phase and anaesthetist as factors. Results: The mean difference between etomidate and propofol in the MAP-time integral below baseline was 2244 mm Hg s (95% confidence interval, 581e3906; P¼0.009), representing a 34% greater reduction with propofol. Overall, vasopressors were used in 10/75 patients in the etomidate group vs 21/75 in the propofol group (P¼0.38), and in 20/74 patients during the blinded phase vs 11/76 during the open-label phase (P¼0.31). The interaction between randomisation and phase (open-labelled or blinded) was not significant for either primary (P¼0.73) or secondary endpoints (P¼0.90). Conclusions: Propofol caused a 34% greater reduction in MAP-time integral from baseline after induction of anaesthesia than etomidate, despite more frequent use of vasopressors with propofol, confirming the superior haemodynamic profile of etomidate in this context. The proportion of patients receiving vasopressors increased slightly, albeit not significantly, in both groups in the blinded phase. Clinical trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12614000717651.
Etomidate produces reliable, rapid onset of anaesthesia and is perceived as having a favourable haemodynamic profile, making it a common choice for patients at risk of hypotension, or where hypotension is undesirable (e.g. in patients who are critically ill, cardiovascularly compromised, or both). However, etomidate also suppresses adrenocortical function. Several retrospective studies have suggested a link between the use of etomidate for induction of anaesthesia and increased risk of mortality in septic or critically ill patients, 1e3 and to an increase in mortality, cardiovascular morbidity, and hospital stay in non-cardiac surgery patients. 4 One retrospective study in cardiac surgery patients did not show any difference in mortality. 5 Despite these potential concerns, many anaesthetists still use etomidate for induction of anaesthesia in cardiac surgery patients, in whom haemodynamic stability immediately after induction of anaesthesia is considered important. There are no large RCTs comparing patient outcomes after etomidate vs propofol induction in patients undergoing cardiac surgery. Such a trial is warranted. Ideally, an RCT comparing propofol and etomidate should be blinded. At the outset of the present study, approximately half of the anaesthetists at our centre routinely selected etomidate over propofol for cardiac surgery patients. Informal inquiry suggested that most anaesthetists would participate in our proposed substantive RCT investigating outcomes if it was not blinded, but many would be reluctant to do so if blinded to induction drug for the purposes of the study. This reflected a concern that acceptable haemodynamic stability would be even more difficult to achieve with propofol if one did not know which drug was being used.
Published studies investigating the haemodynamic profile of etomidate and propofol in cardiac surgery patients are few. Existing studies exhibit methodological drawbacks, such as retrospective design and vulnerability to selection biases 6 ; small sample sizes 7, 8 ; failure to consider the induction period 6, 9, 10 ; and comparison of blood pressure differences at specific postinduction time points instead of the continuous trend over time. 11e13 Thus, before embarking on a large RCT investigating patient outcomes after induction by etomidate vs propofol in patients undergoing cardiac surgery, it was important to establish the haemodynamic superiority of etomidate in this context, as that is currently the only justification for preferring etomidate.
We therefore aimed to test the hypothesis that etomidate is superior to propofol for induction of anaesthesia in relation to haemodynamic stability over the first 10 min after induction, in patients undergoing cardiac surgery. We had two secondary objectives related to planning a future trial focused on clinically relevant outcomes. These were: (1) to determine whether blinding of these study drugs has an impact on clinical practice, and consequently the haemodynamic stability associated with their use; and (2) to establish the feasibility of calculating days alive and out of hospital (DAOH) for 90 days after surgery (DAOH 90 ) from information in New Zealand's National Minimum Dataset. DAOH is a statistically powerful measure of outcome after surgery, and its use could reduce the required sample size, and hence increase the feasibility of such a clinical trial. 14 
Methods
This was a randomised, controlled superiority trial with openlabel (unblinded) and blinded phases conducted at the Green Lane Cardio-thoracic Surgery Unit, Auckland, New Zealand. The study was approved by the Northern A Health and Disability Ethics Committee, Wellington, New Zealand (Reference 14/NTA/67), and registered with the Australian New Zealand Clinical Trials Registry (ACTRN12614000717651). All participants gave written, informed consent.
Participants, randomisation, and blinding
Participants were cardiac surgery patients aged 18 yr or older, with ASA physical status 2e4, who were scheduled to undergo elective coronary artery bypass grafting (CABG), valve surgery, combinations of CABG and valve surgery, or thoracic aorta surgery. We excluded those patients who had a documented allergy to etomidate or propofol, or who were scheduled for transplant surgery. Patients were randomised to receive propofol or etomidate (1:1) for anaesthetic induction, with stratification by anaesthetist. During Phase I, the study was openlabel; the anaesthetist was provided with the randomisation code and was not blinded to the induction agent (propofol or etomidate). During Phase II, all clinical and study staff were blinded to the induction agent. The head anaesthetic technician was provided with the concealed allocation code immediately before the start of the case and drew up the designated drug in two 10 ml syringes. Syringes were labelled with a barcoded 'induction agent' label for use with our institution's anaesthetic information management system (AIMS) (Safer Sleep LLC, Nashville, TN, USA). We used the standard concentrations of propofol (10 
Anaesthesia
At the attending anaesthetists' discretion, intravenous midazolam was administered for anxiolysis and fentanyl for ablation of the sympathetic response to intubation and initiation of surgery, before administration of the induction agent. Induction of anaesthesia was then achieved through titration of the allocated study drug to achieve loss of responsiveness to verbal command. After induction, blood pressure was supported to a level determined by the anaesthetist as appropriate for the patient using bolus doses of metaraminol (0.25e0.5 mg) or ephedrine (3e6 mg). Neuromuscular block was achieved using a nondepolarising neuromuscular blocking agent. Before cardiopulmonary bypass, anaesthesia was maintained using volatile anaesthetics, as is usual at our centre. Propofol was subsequently administered as an infusion starting with onset of cardiopulmonary bypass until the end of each case and to maintain sedation during transfer to the postoperative care unit. Patients were monitored according to the standards of the Australian and New Zealand College of Anaesthetists, with direct measurement of arterial pressure. Arterial catheters were inserted for this purpose before induction of anaesthesia. Central venous catheters or, in some cases, pulmonary artery catheters were inserted after induction of anaesthesia, before surgical incision.
Data collection
Mean arterial pressure (MAP) was recorded automatically by our AIMS with a sampling period of 30 s throughout the anaesthetic. These data were incorporated into the automatically generated anaesthetic record, with intraoperative drug administrations entered using the barcoding system of the AIMS. An observer recorded the number of boluses and total amount of vasoactive drugs administered in the first 10 min after induction of anaesthesia. Blood pressure and drug dosing information for each patient were subsequently extracted from the electronic anaesthetic records. Other data describing patient characteristics, surgical procedures, and anaesthetics were extracted from their anaesthetic records or clinical notes.
Endpoints
Baseline MAP was defined as the mean MAP over the 3 min period immediately before induction. Our primary endpoint was the area under the baseline MAP over the first 10 min after induction, called the MAP-time integral. The calculation process is illustrated in Supplementary Figure S1 . We compared this endpoint between Phases I and II in order to evaluate the effect of blinding the induction agent.
Outcome analysis
We also collected the information (i.e. admission and discharge dates) required to calculate DAOH 90 for all patients. This variable was defined as the total study follow-up period (taken as 90 postoperative days) minus the number of those study days in hospital, number of days dead, or both, and presented as a percentage. 15 The calculation of DAOH 90 was performed manually for each patient.
Statistical analysis
The primary outcome measure was compared between groups using a general linear model (GLM). For the purpose of statistical analysis the use of vasopressor drugs within 10 min of induction was collapsed to a binary variable (0¼no boluses, 1¼one or more boluses) and compared between groups using logistic regression, with results summarised as odds ratios (OR) with 95% confidence interval (CI). Both endpoints were compared between groups with stratification factors controlling for covariates of anaesthetist, study phase (open-label or blinded), and baseline MAP. To test whether blinding altered the relative effects of the two randomised induction drugs, the interaction term 'study phase Â randomised drug' was tested in the models.
Sample size
We previously used a similar methodology and patient population to investigate non-inferiority of clevidipine with respect to nitroglycerin for blood pressure control. 16 We identified a coefficient of variation (CV) of 66% for the area under the curve (AUC) MAP of nitroglycerin as clinically significant. Similarly, by consensus amongst those investigators who are anaesthetists, we defined a clinically relevant effect as a betweengroup difference in the AUC (reduction from baseline MAP over 10 min after induction) of 33.3% or more. For this effect size, and on the assumption that variance would be somewhat similar for the drugs in the present study and the clevidipine study, we estimated that 76 patients per study arm would be needed to demonstrate superiority (a<0.05, one-sided) with 90% power. Consequently we aimed to study 38 patients in each arm of the study in both Phase I (n¼76) and Phase II (n¼76), giving 152 patients in total ( Supplementary Fig. S2 ).
Results
Data were collected between August 2014 and August 2015. The flow of participants through the study is given in Figure 1 . Subject characteristics and details of surgery are summarised according to group in Table 1 . We randomised 156 patients, but four were excluded before surgery, leaving a total of 152 subjects who actually entered the study. A further two subjects were excluded because of corrupted or lost electronic records. This resulted in 75 subjects per study drug group, but a slightly uneven split when compared by phase (open-label vs blinded); the groups were well balanced with respect to relevant demographic and other baseline factors (see Table 1 and Supplementary  Table S1 ). The mean induction doses of propofol were similar between phases, whereas the etomidate dose was greater in the blinded phase than in the open-label phase. Inhalation anaesthetics were used to maintain anaesthesia during the 10 min study period in 141 cases (see Supplementary Table S2 ) before or after induction.
Primary endpoint
The administration of either etomidate or propofol at induction was followed by a net reduction in MAP in the first 10 min thereafter ( Table 2 ). Using data from both blinded and openlabel phases combined, the mean (SD) MAP-time integral (AUC) below baseline was e6595 (5404) mm Hg s for etomidate and e8839 (5355) mm Hg s for propofol, giving a mean difference of 2244 (95% CI, 581e3906) mm Hg s (from the GLM adjusted for phase, anaesthetist, and baseline MAP: P¼0.009). This represents a 34% (95% CI, 9e59%) greater reduction with propofol, which is greater than our predefined level of clinical importance (33.3%; see Fig. 2 ).
Secondary endpoints
Administration of vasopressor agent over the first 10 min after induction. Table 3 subjects received vasopressor administrations in the etomidate arm and nine of 40 in the propofol arm. In Phase II (blinded), the total number of subjects receiving vasopressor administrations was eight of 39 for etomidate and 12/35 for propofol. Induction drug (P¼0.38) and phase (P¼0.31) were not significant predictors of the vasopressor administration in the regression analysis. The lowest MAP recorded, and the largest reduction in MAP, during the 10 min after induction are presented by drug, study phase, and vasopressor use in Supplementary Table S2 .
Effect of blinding the anaesthetist to induction agents
The mean AUC below baseline was 1467 mm Hg s (95% CI, e348 to 3282), or 21% (95% CI, e5%e47%), greater in Phase II (blinded), P¼0.11. Differences in MAP-time integral for each drug by phase compared with open-label etomidate are depicted in Figure 3 . Vasopressors were used in 20/74 patients during the blinded phase vs 11/76 during the open-label, phase giving an OR of 2.12 (95% CI, 0.50e9.03), P¼0.31, as summarised in Table 3 . When an interaction term (induction drug Â phase) was included in the model, its effect on both the primary and key secondary endpoints was non-significant (P¼0.73 and 0.90, respectively).
Outcome analysis
DAOH data were available for all subjects. The data were strongly skewed, with a median (inter-quartile range) percent DAOH of 90 (84e92).
Discussion
The use of propofol for induction of anaesthesia was followed by a 34% greater reduction in the area below baseline for MAP than the use of etomidate (P¼0.009). This figure is in excess of our predefined measure of a clinically important difference. The administration of vasopressor was more frequent with propofol (although this difference was not statistically significant) so we can be confident that the use of vasopressor did not confound our primary finding, although it may perhaps have reduced its magnitude. These data support the prevalent view that etomidate causes less haemodynamic instability than propofol when used for induction of general anaesthesia in cardiac surgical patients.
Others have compared propofol with etomidate for induction of anaesthesia in cardiac surgery patients. At least four randomised trials have been reported. 8 (14) 23 ( are the only studies where blinding to study drug has been used. In patients with severe aortic stenosis, Bendel and colleagues 12 found a statistically significant reduction of 15% in the lowest mean MAP with propofol in comparison with etomidate when the BIS reached 60 after induction, whereas Soleimani and colleagues 13 reported similar findings with an increased use of ephedrine in the propofol arm. Others have also demonstrated similar decreases in MAP (~15 mm Hg) with propofol at single time points after induction in both cardiac and non-cardiac surgery patients. 11,17e19 We chose to take an integral over the 10 min period after administration of induction agents to avoid making multiple comparisons at predefined time points that might not be comparable between patients (because of timings of endotracheal tube insertion or other stimuli), and to better capture whether reductions in MAP were sustained over the minutes after induction. We believe our approach, with inclusion of baseline MAP as a covariate in our analysis, stratification for anaesthetist, and larger sample size, provides the most robust comparison of haemodynamic profiles with these induction drugs in this patient group to date. Our study is the only one which has compared the effect of including both blinded and open-label phases. Our primary interest in doing so was to inform the planning of a future prospective study focused on the outcomes associated with each drug. For such a study, blinding would generally be considered ideal. However, in the context of these two drugs, there might be advantages to an open label design. Aside from avoiding expense and complexity of day-to-day study logistics, our anecdotal experience indicates that recruitment of anaesthetists would be easier. Although some of our anaesthetists were happy to participate in the blinded limb of this study, others were less comfortable about doing so. These are important considerations in relation to the feasibility of a large pragmatic study. Although we found that blinding the induction agent did not have a statistically significant effect on MAP, it did result in a significant departure from standard clinical use of etomidate. There was a 3.2-fold increase in the per kg dose of etomidate in the blinded phase vs the open label phase (see Table 1 ), suggesting a tendency to treat the unknown induction agent as if it were propofol. Therefore, on balance, we would recommend that in a future large, prospective, outcomes-focused comparison between these two agents, the anaesthetist responsible for patient care at the time of anaesthetic induction should not be blinded to the allocation of the drug, as blinding might lead to a substantial change in practice. Such a change might not be consistent with current standard of care, and could conceivably influence patients' downstream clinical outcomes. All other clinicians, investigators, and the patients themselves, should be blinded to study group allocation (propofol vs etomidate) in this scenario.
There are various methods that we could have used to analyse data, so it is an important strength that we prespecified and registered our primary endpoint: the area under the baseline MAP in the 10 min period after induction. We chose this approach because we were interested in the reduction in blood pressure after the administration of our study drugs, and had no foundation for an expectation that these drugs would cause any increase in MAP. There is some evidence to suggest that hypertension may occur more frequently with etomidate than propofol, 18 but elevations in MAP may also reflect the use of vasopressors, and any noxious stimulus occurring in the first 10 min after induction of anaesthesia (such as intubation). In any event, increases in MAP above baseline do not serve to compensate for periods of hypotension, and we therefore believe our approach to this analysis is correct in the context of our research question. We acknowledge the arbitrary nature of designating a 33.3% difference in MAP-time integral below baseline as 'clinically relevant', but there are no data upon which to base a more objective endpoint and, importantly, we chose our value prospectively.
In this study, we have addressed a question whose answer has long been assumed: is etomidate superior to propofol in relation to haemodynamic stability during induction? Had there been no difference in haemodynamic stability between these two drugs, the concerns over etomidate's effects on adrenocortical function would provide a compelling reason to avoid its use. However, in this study propofol caused a 34% larger reduction in the area under baseline MAP after induction than etomidate despite more frequent use of vasopressor drugs. We can therefore conclude that, when used for induction of anaesthesia, etomidate provides superior haemodynamic stability to propofol. This provides justification for proceeding to a large open-label prospective randomised study to provide a definitive answer to the question of whether its use for induction of anaesthesia in patients undergoing cardiac surgery is associated with worse long-term outcomes when compared with propofol. We have demonstrated that the use of DAOH as an outcome measure in such a trial would be feasible in our setting. The absolute and percentage difference in the area under the baseline mean arterial pressure (MAP) between propofol and etomidate by study phase. Etomidate, Phase I, is taken as the reference point. The shaded area depicts a difference in MAP of up to 33.3% (we defined a difference of 33.3% or more as clinically relevant). In Phase I the study was open-label whereas in Phase II anaesthetists were blinded to study drug. The error bars represent 95% confidence intervals.
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